title: Monitoring of endogenous interferon-alpha and human herpesvirus 8 in HIV-infected patients with Kaposi's sarcoma.
abstract: The incidence of AIDS-associated Kaposi's sarcoma has declined since the mid-nineties due to the availability of potent antiretroviral therapy including protease inhibitors. However, Kaposi's sarcoma is still the most common neoplasia in HIV-infected patients. In the pathogenesis of the HIV-associated as well as other forms of this disease an infectious agent seems to play a role, namely the human herpesvirus 8. Even before the discovery of the HIV virus, high levels of an unusual acid-labile form of endogenous interferon alpha were found in patients with AIDS-associated KS. The administration of recombinant interferon alpha evolved as standard therapy for Kaposi's sarcoma in HIV-infected patients with a moderate immunodeficiency in addition to antiretroviral therapy. This investigation monitored the levels of HHV 8 and endogenous interferon in 4 patients with and without Kaposi's sarcoma during the course of HIV-disease. The results of our experiments lead us to two hypotheses: First of all, the pre-therapeutic level of endogenous interferon may be a predictor of the response to an interferon-alpha therapy for HIV-associated Kaposi's sarcoma. Secondly, the determination of HHV 8 DNA in blood of HIV-positive patients may allow conclusions about the risk for the development of Kaposi's sarcoma. However these hypotheses should be tested by monitoring the levels of endogenous interferon and HHV 8 DNA in clinical studies of a greater number of HIV-infected patients.
authors.affiliation: Institute for interdisciplinary infectiology and immunology GmbH, General Hospital St. Georg, Lohmühlenstr. 5, D-20099 Hamburg, Germany. plettenberg@ifi-infektiologie.de
authors.forename: A
authors.initials: A
authors.lastname: Plettenberg
authors.forename: D
authors.initials: D
authors.lastname: Albrecht
authors.forename: T
authors.initials: T
authors.lastname: Lorenzen
authors.forename: T
authors.initials: T
authors.lastname: Meyer
authors.forename: R
authors.initials: R
authors.lastname: Arndt
authors.forename: A
authors.initials: A
authors.lastname: Stoehr
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D004279:DNA, Viral / Q000097:blood; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000821:virology*; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D016898:Interferon-alpha / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000821:virology
chemical_list: D004279:DNA, Viral; D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins